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Indomethacin, a known inhibitor of prostaglandin synthesis, administered topically as a 
2.5% solution, intradermally in 10-~-tg doses, and orally in a dose of 150 mg/day for 2 days, did 
not diminish the delayed erythema produced by long-wave ultraviolet light (320-400 run). 
The delayed phototoxic erythema produced by 8-methoxypsoralen and subsequent exposure 
to long-wave ultraviolet light was similarly unaffected. By comparison, topical and intrader-
mal indomethacin treatment produced sustained decrease in the erythemal response to 
ultraviolet radiation in the UVB range (290-320 nm). 
Indomethacin is a nonsteroidal, anti-inflamma-
tory agent which topically [11 and intradermally 
l2J can decrease the delayed erythema produced in 
human skin by exposure to ultraviolet radiation in 
the UVB range (290-320 nm). Furthermore, oral 
indomethacin has been shown to reduce the cuta-
neous blood flow response [3] and erythema [4] 
induced by UVB radiation . Since indomethacin 
has the property of inhibiting prostaglandin syn-
thesis [51, these findings support the suggestion 
that prostaglandins are mediators of the delayed 
erythemal response to UVB radiation [6, 7) and 
hence to sunburn. Long-wave ultraviolet radiation 
(UV A, 320--400 nm) and UVB differ in both their 
propert ies and effects. Approximately a 1000 times 
greater exposure dose (energy/surface area) of 
UV A than UVB is required to induce delayed 
erythema in human skin [8). When UV A and 
UVB irradiation are applied in doses sufficient to 
produce equivalent degrees of delayed erythema, 
UV A irradiation is more likely to cause immediate 
erythema, elevation of skin temperature, and pain 
[9). The UV A-induced delayed erythema is likely 
to have a violaceous hue, suggesting deeper vessel 
involvement. UV A causes similar acute dermal 
changes as those seen with UVB but wjth less 
epidermal change (lOJ. The introduction of the 
photosensitizer, psoralen, further a lters the prop-
erties of the delayed erythema in that it requires 
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Abbreviations: 
MED: minimum erythema dose 
MPD: ll'linimum phototoxic dose 
PUV A: psoralen-UV A 
UVA: long-wave ultraviolet (320-400 nm) 
UVB: middle-wave ultraviolet (290-320 nm) 
less energy, peaks much later , and has a steeper 
erythema/energy dose-response curve than noted 
with UVA alone (J . A. Parrish, unpublished ob-
servation). Taking into account all the differences 
between UVB and UV A with and without psora-
len, it would not be surprising to find that their 
cutaneous effects involve different mediators. 
The present study was undertaken to determine 
the effects of indomethacin administered topica11y, 
intradermally , and orally on the delayed phase of 
the erythemal response to ultraviolet r adiation in 
the UVA range both with and without the addi-
tion of a photosensitizer. For comparison, the ef-
fect of indomethacin on UVB-induced erythema 
was a lso studied in the same subjects. 
MATERIALS AND METHODS 
Su.bjects 
The untanned back skin of fair-skinned Caucasians 
was w;ed in all parts of the study. Informed consent was 
obtained from 12 healthy volunteers ranging in age 
from 20 to 28 years. 
Light S ystems 
Polychromatic UV A : xenon arc solar simulator 
(emission spectrum 320-400 nm with a Schott WG355 
fil ter, Solar Light Company). 
Monochromatic UVA : 337.1-nm nitrogen-pulsed 
laser (Avco Corporation). 
PUVA ( psoralen- UV A ): orally administered 8-meth-
oxypsoralen (0.6 mg/ kg) and subsequent exposure 2 hr 
later to a high-intensity fluorescent UV A source (emis-
sion spectrum 320-400 nm, GTE Sylvania [11]). 
UVB: fluorescent tubes (major emission spectrum 
290-320 nm, Westinghouse FS40). 
The output of UVB a nd UV A from t he UV A light 
sources (solar simulator and Sylvania) was measured 
using a n IL700 research radiometer and a ppropriate 
filters CNB297 for UVB and WB350 for UV AJ. For the 
solar simulator the output was 20 JJ-W/cm~ of UVB, 70 
mw/cm2 of UVA (<0.026% UVB), and for the Sylvania 
unit the output was 15 IJ-W/cm~ of UVB, 7.4 mw/cm2 of 
UVA (<0.2% UVB). 
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Light Testing 
As an initial step on each subject, the m1mmum 
erythema dose (MED = minimum exposure required to 
produce a detectable erythema with definite margins) 
was determined for both UVB and UVA. For UVB a 
range of 20-90 mJ/cm2 with increments of 10 mJ/cm' 
and for UVA, 20-160 J /cm2 with increments of20 J/cm~. 
was used. In addition, the minimum phototoxic dose, 
MPD, was determined. MPD is the minimum UVA 
exposure given 2 hr after oral medication with 8-meth-
oxypsoralen required to produce a detectable erythema 
with definite margins at 48 hr after expos\lre. A range 
of 1-8 J /cm" of UV A with 1 J /cm2 increments a nd a 
drug dose of 0.6 mg/kg were used. ln all phases of the 
experiments, UVA and UVB exposures were given 
first, psoralen was then administered, and the subject 
exposed to UVA 2 hr later. 
Erythema was graded as follows: 0 = no erythema; 
1 + = pink erythema with definite margins; 2-"- = red 
erythema with no edema; 3+ = fiery-red erythema with 
edema. Blanching was graded on the basis of obvious 
reduction of one erythema grading when the treated 
site was compared with control, untreated site. Ery-
themal responses were examined at 24 hr ( UVB and 
UVA) and 48 hr (UVA and PUVA> after exposure. In 
addition, all irradiated sites were examined 14 days 
later to assess the pigment response. 
Topical In domethacin Study (5 Subjects) 
Using the MED and MPD results as a guide, expo-
sure doses judged sufficient to produce a 2+ erythema 
were given (4 x MEDevo to 1.5 em square, 2 x MEDn·, 
to 0.5 x 5 em using the laser as a light source, and 2 x 
MPD.,t'~'' Lo 1.5 em square). Three adjacent sites were 
exposed to each light source: one was treated with 
indomethacin, one was treated with vehicle alone, and 
the third was left untreated. lndomethacin was applied 
as a 2.5* solution in propylene glycol:ethanol:di-
methylacetamide. 19:19:2 (v/v) m 20-11-l volumes. The 
Table outlines the protocol followed in each subject. 
lntradermallndomethacirl Study f2 Subjects! 
As in the topical study. exposure doses were given 
with the aim of producing a 2+ erythema. For each 
light source three adjacent sites were exposed: one was 
injected with indomethacm, one was injected with vehi-
cle alone. and one was left untreated. Indomethacin 
was injected intradermally into the center of the ex-
posed sites in a dose of 10 !Lg in 0.05 ml of 0.9'* sterile 
saline. The UVB-ex:posed sites were injected at zero 
time, 2 hr, and 24 hr after exposure. The solar simula-
tor was used as the UV A light source and those sites 
TABLE . Topical indomethacin study 
Sub-
Ject Light exposure 
no. 
UVB 
UVA 
PUVA 
UVB 
2. 3 UVA 
PUVA 
4, 5 PUVA 
Apphcailon times aft.er light 
exposure ( hr) 
4 
0, 24, 48 
0, 24. 48 
0, 1, 2, 3, 4, 24 
0, 24, 48 
0, 24 , 48 
0; half-hourly for 
8 hr on day 1 
and day 2; 48 and 96 
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and the PUVA sites were injected at zero time, 24 hr, 
and 48 hr after exposure because the latter delayed-
erythema reactions are expected to maximize later lhan 
those seen with UVB. 
Ora/Indomethacin Stud)• (6 Sub;ects) 
Four subjects were exposed to the UVB light source, 
the solar simulator, and to PUVA, and two subjects 
were exposed to UVB and PUV A only. An MED to UV A 
and to UVB and an MPD to PUV A were first deter-
mined on one side of the subject's back (1.5 em squares). 
In addition, a flxed exposure from each light source was 
given on a larger area (4 em square) with the aim of 
producing a grade 2+ to 3- erythema. After these 
results were read at 24 and 48 hr, the same procedure 
was repeated on the other side of the back. Oral indo-
methacin was commenced 1 hr before this second set of 
exposures and continued for 2 days in a dose of 50 mg 3 
times a day. Readings taken before and during indo-
methacin administration were then compared. 
RESULTS 
Topical indomethacin . A strong 1 + to 2 + ery-
thema was produced at each exposure site. 
Blanching of UVB-induced delayed erythema was 
seen at each indomethacin-treated site. In subject 
1, a 1 + blanch appeared at 2 hr after application 
and was sustained for 5 hr. In subjects 2 and 3, a 
1 + blanch was detected 4 hr after exposure and 
application of indomethacin and this was still evi-
dent at 48 hr. No blanching was seen at the UVB-
exposed s ites treated with vehic1e alone. No 
blanching was seen in any of the PUV A or UVA 
laser-exposed sites whether treated with indo-
methacin or vehicle. 
l ntradermal indomethacin . A strong 1+ to 2-r 
erythema was produced at each exposure site. In 
both subjects, the indomethacin-injected, UVB-ex-
posed sites showed a 1 + blanch which was sus-
tained for 6 hr. The vehicle-treated, UVB-exposed 
site did not show blanching. The PUV A and UV A-
exposed sites did not show any blanching in either 
subject when treated with indomethacin or vehi-
cle. 
Oral indomethacin . In 5 of 6 subjects, the MED 
to UV A and to UVB, the MPD to PUV A, and the 
responses at the larger 2 + erythema sites result-
ing from a fixed exposure to each light source, 
were unaltered by indomethacin administration. 
In one subject all erythemal responses were re-
duced in conjunction with indomethacin adminis-
tration: UVB was reduced by 20<rC , UV A by 25~, 
and PUV A by 200o/c . 
Pigmentation. No differences in degree of pig-
mentation were detected between treated and un-
treated sites. 
DISCUSSION 
While this study has confirmed the observation 
that topical and intradermal indomethacin re-
duces the erythemal response to UVB radiation , it 
has shown that, within the limits tested here, the 
erythemal response to UV A radiation is not al-
tered by indomethacin. Topical and intradermal 
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indomethacin did not produce any effect on the 
delayed erythema induced by UV A radiation with 
and without the addition of an oral psora len photo-
sensitizer, 8-methoxypsoralen. Comparison stud-
ies between UV A- and UVB-induced delayed ery-
thema are compromised by the fact that markedly 
different radiation doses are required. In this 
study. an equal degree of redness was used, but 
such judgements are difficult to quantitate. Stud-
ies are further complicated by the fact that the 
timing of the UV A-induced erythema is variable 
and may be related not only to the choice of wave-
lengths within the 320-400 nm spectrum but also 
to the intensity of radiation; large energy doses of 
UV A may cause immediate erythema, heating ef-
fects, and variable peaks in timing of delayed 
erythema 19.12). Despite these difficulties it can be 
stated that topical and intradermal indomethacin 
applied 24 hr after irradiation caused blanching of 
UVB erythema and not of UV A erythema. The 
delayed erythema curve associated with oral psor-
alen and subsequent UV A requires less energy 
than when using UV A alone and is better charac-
terized [131 as far as dose-response curve and time 
course. There is a longer interval between the 
ultraviolet exposure and the onset of the redness. 
the redness takes longer to reach its peak. and it 
lasts longer . PUVA redness may be absent or just 
beginning at 12 to 24 hr after ultraviolet exposure 
(when UVB or sunburn erythema is normally at 
its peak), and may not peak until 48 to 72 hr or 
later. In addition, the erythema dose-response 
curve is steep. In the presence of psoralens, small 
increases in UV A cause marked increase in ery-
thema. Despite applications of indomethacin soon 
after radiation and at the time of peak erythema 
response (Tab. l no change was seen in this ery-
thema reaction. 
Oral indomethacin produced no effect on the 
UV A erythemal responses in 5 of 6 subjects exam-
ined here and this finding supports the results 
obtained with the other two routes of administra-
tion. Two reports 13,4] have indicated that oral 
indomethacin reduces the vascular responses to 
UVB radiation but this was not the finding in the 
present study. Five of the six subjects examined 
showed the same erythemal response both before 
and v:ith oral indomethacin. There are considera-
ble problems involved in designing a study for the 
accurate assessment of the effect of an oral agent 
on UV inflammation since some form of before and 
after comparison is necessary, and observation of 
degrees of erythema is not a very precise art. 
Furthermore different methodology was used in 
the previous studies. One study 13] used xenon gas 
clearance from skin to measure blood flow re-
sponse to radiation without a direct assessment of 
erythema, while the other study [4] statistically 
analyzed erythemal responses in a group of sub-
jects after a single dose of drug or placebo. 
All light-exposed sites were examined 14 days 
after exposure to determine whether blanching of 
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erythema by indomethacin altered the subsequent 
pigmentary response. The UVB sites that had 
blanched with indomethacin applied topically and 
intradermally showed the same degree of pigmen-
tation as comparable sites treated with vehicle 
alone or left untreated. It has been reported 11,14] 
that indomethacin blanching of UVB erythema 
does decrease the depth of the subsequent pigmen-
tation. This warrants further investigation as it is 
an important observation in the understanding of 
the mechanism of melanogenesis. 
A previous report 115] bas found that UVC-
induced erythema is not blanched consistently by 
intradermal indomethacin in the doses required to 
produce an effect in UVB erythema. This. coupled 
with the present observations that a similar dose 
of indomethacin does not influence UV A ery-
thema. indicates that the influence of this agent 
may be limited to the UVB range of ultraviolet. 
radiation. This finding is important because. 
while sunburn erythema results mainly from 
UVB, there may also be a contribution from UVA. 
It could therefore be expected that indomethacin 
would be less effective in blanching an erythema 
from sunlight as compared with an equally intense 
erythema from a UVB radiation source. 
A major action of indomethacin is to inhibit 
prostaglandin synthesis and therefore the finding 
that this agent blanches UVB-induced er.vthema 
provides some indirect. evidence that prostaglan-
dins may be the mediators of this erythema. It 
follows that our failure to produce blanching of 
UV A-induced er.vthemas with indomethacin pro-
vides indirect evidence that prostaglandins may 
not be involved as mediators of UV A erythema. 
Further work is necessary to provide direct mea-
surements of prostaglandin production in response 
to UV A radiation to resolve this issue. 
We wish to tha nk Mr. Timothy Kingsbury for his 
excellent technical help. 
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